Stockholm Stock Exchange | Mid Cap
Calliditas
+144.55%
Latest
+102.30%
3 months
Pareto SecuritiesSEBGuggenheim SecuritiesKepler CheuvreuxCarnegieBryan GarnierCiti Investment ResearchKempenSEB Equities

About The Company

Calliditas vision is to leverage its interdisciplinary expertise in pharmaceutical product development to identify, develop and commercialize novel treatments in orphan indications, with an initial focus on renal and hepatic diseases with significant unmet medical needs.
Calliditas